Budin Corina Eugenia, Cocuz Iuliu Gabriel, Enache Liviu Sorin, Rența Ionuț Alexandru, Cazacu Cristian, Pătrîntașu Dariana Elena, Olteanu Mihai, Râjnoveanu Ruxandra-Mioara, Ianoși Edith Simona, Râjnoveanu Armand, Cotoi Ovidiu Simion
Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, 540139 Târgu Mureș, Romania.
Pneumology Department, Clinical County Hospital Mureș, 540136 Târgu Mureș, Romania.
Cancers (Basel). 2024 Aug 21;16(16):2903. doi: 10.3390/cancers16162903.
Analysis of inflammatory biomarkers, along with the neutrophil/lymphocyte ratio (NLR) or platelet/lymphocyte ratio (PLR), supports the connection between inflammation and carcinogenesis. We conducted a retrospective observational study at the Clinical County Hospital Mureș involving patients with lung cancer. The parameters analyzed included histopathological type (NSCLC: squamous cell carcinoma or adenocarcinoma; SCLC), molecular mutations (EGFR, ALK, PD-L1), parameters from the complete blood count, inflammatory parameters, and associated comorbidities. A total of 380 patients were included: 115 patients in the cancer group and 265 patients in the control group. Among patients in the lung cancer group, 88 were diagnosed with NSCLC (44 adenocarcinomas, 44 squamous cell carcinomas) and 27 with SCLC. Both NLR and PLR were significantly higher in cancer patients than in the control group (5.30 versus 2.60, < 0.001; 217 versus 136, < 0.001, respectively). NLR and PLR differ between men and women ( = 0.005 and = 0.056, respectively). C-reactive protein was not correlated with either NLR (-value: 0.0669) or PLR (-value: 0.6733) in lung cancer patients. The NLR and PLR values may serve as new predictive biomarkers for the diagnosis of disease in patients with lung cancer, especially those with NSCLC.
对炎症生物标志物以及中性粒细胞/淋巴细胞比率（NLR）或血小板/淋巴细胞比率（PLR）的分析，支持了炎症与致癌作用之间的联系。我们在穆列什县临床医院对肺癌患者进行了一项回顾性观察研究。分析的参数包括组织病理学类型（非小细胞肺癌：鳞状细胞癌或腺癌；小细胞肺癌）、分子突变（表皮生长因子受体、间变性淋巴瘤激酶、程序性死亡受体1）、血常规参数、炎症参数以及相关合并症。总共纳入了380例患者：癌症组115例患者，对照组265例患者。在肺癌组患者中，88例被诊断为非小细胞肺癌（44例腺癌，44例鳞状细胞癌），27例为小细胞肺癌。癌症患者的NLR和PLR均显著高于对照组（分别为5.30对2.60，<0.001；217对136，<0.001）。NLR和PLR在男性和女性之间存在差异（分别为=0.005和=0.056）。肺癌患者中，C反应蛋白与NLR（-值：0.0669）或PLR（-值：0.6733）均无相关性。NLR和PLR值可作为肺癌患者，尤其是非小细胞肺癌患者疾病诊断的新预测生物标志物。
